SpeedyGonzalesi

@chaperonycon

Biotech investor with a strong focus on biosimilars and biobetters. Innovation needs the pressure from patent cliffs.

Vrijeme pridruživanja: ožujak 2015.

Tweetovi

Blokirali ste korisnika/cu @chaperonycon

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @chaperonycon

  1. 2. velj

    Die Bundesregierung hat keinen breit angelegten Notfallplan gg eine Epidemie aufgestellt. Schulen, KiTas, TV müßten Desinfektionshinweise geben. Ärzte zu richtiger Diagnose geschult, Apotheken mit Atemschutzmasken bevorratet werden.

    Poništi
  2. 1. velj

    With the sales growth seen so far and the likely addition of a Remicade biosimilar, Bernstein analyst Ronny Gal said "it's tough to see " Amgen 2020 biosimilar sales of less than $1.8 billion, up from $570 million in 2019.

    Poništi
  3. 31. sij

    „Severin Schwan geht dieses Jahr von rund vier Milliarden Franken Umsatzeinbußen durch sogenannte Biosimilars aus nach etwa 1,5 Milliarden Franken 2019.“

    Poništi
  4. proslijedio/la je Tweet
    31. sij

    The ‘benefit:risk grid’ from my recent talk on Positioning Therapies. We’re still missing an agent for the top left..

    Poništi
  5. proslijedio/la je Tweet

    Und weiter mit den schlechten Nachrichten zu : Wissenschaftler der Universität Hong Kong gehen davon aus, dass die Situation in außer Kontrolle ist und in vielen weiteren chinesischen Großstädten binnen 14 Tagen eskalieren könnte.

    Poništi
  6. proslijedio/la je Tweet
    28. sij
    Poništi
  7. proslijedio/la je Tweet
    28. sij

    Humira biosimilars now controlling almost 40% of the market in the EU, according to Bernstein. The UK and Germany are outpacing the others... ...and the US looks on in shame, swallowing another 7.4% price increase from AbbVie for 2020

    Prikaži ovu nit
    Poništi
  8. 28. sij

    And in Q2 clinical sites in US start recruiting PH2b UC. A financing plan therefore should be prooved. Wished speed in recruitment will make some costs

    Poništi
  9. 27. sij

    "Roughly 80% of active ingredients used by commercial sources to produce finished medicines come from China, Christopher Priest, deputy assistant director at the U.S. Defense Health Agency"

    Poništi
  10. proslijedio/la je Tweet
    26. sij

    Anti-drug antibodies (ADAs) in various anti-PD1/PD-L1 mAbs: nivolumab 11% pembrolizumab 2 % atezolizumab 30-42 % CX-072 77%

    Prikaži ovu nit
    Poništi
  11. 23. sij

    The promotion by forbes and der aktionär are imo small hints for a capital increase. Why searching the public when we are shortly before a big deal?

    Poništi
  12. 23. sij

    22-24% price discount is for the moment quite moderate. The question is however, what are the discounts mediated in the backroom.

    Poništi
  13. 23. sij

    Nice wants more dicount for recommendation of in GB (ulcerative colitis)

    Poništi
  14. 22. sij

    change of reimbursement conditions is a key to success for costs of healthcare and producers.

    Poništi
  15. 20. sij

    Perhaps abivax has used a specific preclinical murine model for crohn`s, to get some light in this indication. (No DSS)

    Poništi
  16. 19. sij

    Korean biosimilar developers belong to the top of the world. S.c. infliximab was a valuable development.

    Poništi
  17. 19. sij

    Both alpha integrin mabs have a convincing security profile in contrast to anti TNFalpha-mabs.

    Poništi
  18. 18. sij

    Be aware of the quality of products, compounding pharmacies with beva portioning have problems with aseptic deliverage, particle-free prod., risk of off label use for physicians. Prefilled syringe could be the key to success. Bioeq and formycon do have the edge here.

    Poništi
  19. 18. sij

    But the coherus strategy is successfull mainly with indications with limited decision-makers. Salesforce can so be limited. Look at the JPM2020 slides. Big indications like RA, allergic reactions, psoriasis are more difficult to distribute economically.

    Poništi
  20. 15. sij

    2020 goals are accomplishing the Phase 3 trial with xlucane and finding a US distribution partner.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·